source
- Verdiva Bio halts phase 2 oral GLP-1 trial after enrolling only eight participantsVerdiva Bio announced it is ending its phase 2 study of VRB-101, a once‑weekly oral GLP‑1 candidate, after the trial fell far short of its enrollment target. The study was intended to evaluate swi…
- Radical Numerics aims to develop general biological intelligence, says CEO Eric NguyenSTAT’s AI Prognosis newsletter features an interview with Eric Nguyen, chief executive of Radical Numerics. The Boston-based startup says it is working toward what it calls “general biological inte…